Tazarotene 0.1 percent cream plus clindamycin 1 percent gel versus tretinoin 0.025 percent gel plus clindamycin 1 percent gel in the treatment of facial acne vulgaris

Dermatology Online Journal

Volumn 13, Issue 3, 2007, Pages

  Tanghetti, Emil ^a   Dhawan, Sunil ^b   Torok, Helen ^c   Kircik, Leon ^d  

^a Center for Dermatology and Laser Surgery   (United States)

^b Center for Dermatology Cosmetic and Laser Surgery   (United States)

^c Trillium Creek Dermatology and Surgery   (United States)

^d Physicians Skin Care PLLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; RETINOIC ACID; TAZAROTENE; ANTIINFECTIVE AGENT; KERATOLYTIC AGENT; NICOTINIC ACID DERIVATIVE; RETINOID;

ACNE VULGARIS; ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; CHILD; COMPARATIVE STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; FOLLOW UP; GEL; HOSPITALIZATION; MIDDLE AGED; OINTMENT; PATHOLOGY; TOPICAL DRUG ADMINISTRATION;

ACNE VULGARIS; ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; CLINDAMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GELS; HUMANS; KERATOLYTIC AGENTS; MALE; MIDDLE AGED; NICOTINIC ACIDS; OINTMENTS; RETINOIDS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TRETINOIN;

EID: 34547167978     PISSN: None     EISSN: 10872108     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Draelos ZD, Tanghetti EA, Tazarotene Combination Leads to Efficacious Acne Results (CLEAR) Trial Study Group. Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis. 2002 Feb;69(2 Suppl):20-9.
2. Richter JR, Forstrom LR, Kiistala UO, Jung EG. Efficacy of the fixed 1.2% clindamycin phosphate, 0.025% tretinoin gel formulation (Velac) and a proprietary 0.025% tretinoin gel formulation (Aberela) in the topical control of facial acne. J Eur Acad Dermatol Venereol. 1998 Nov;11(3):227-33.
3. Cambazard F. Clinical efficacy of Velac, a new tretinoin and clindamycin phosphate gel in acne vulgaris. J Eur Acad Dermatol Venereol. 1998 Sep;11 Suppl 1:S20-7; discussion S28-9.
4. Leyden JJ, Krochmal L, Yaroshinsky A. Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. J Am Acad Dermatol. 2006 Jan;54(1):73-81. Epub 2005 Nov 28.
5. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003 Jul;49(1 Suppl):S1-37.
6. Webster GF, Berson D, Stein LF, Fivenson DP, Tanghetti EA, Ling M. Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. Cutis. 2001 Jun;67(6 Suppl):4-9.
7. Leyden JJ, Tanghetti EA, Miller B, Ling M, Berson D, Lee J. Once-daily tazarotene 0.1 % gel versus once-daily tretinoin 0.1 % microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial. Cutis. 2002 Feb;69(2 Suppl):12-9.
8. Webster GF, Guenther L, Poulin YP, Solomon BA, Loven K, Lee J. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris. Cutis. 2002 Feb;69(2 Suppl):4-11.
9. ZianaTM prescribing information. Available at: http://www.medicis.com/ products/pi/pi_ziana.pdf. Accessed March 16, 2007.
10. Leyden JJ, Krochmal L, Yaroshinsky A. Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. J Am Acad Dermatol. 2006 Jan;54(1):73-81. Epub 2005 Nov 28.
11. Tanghetti E, Abramovits W, Solomon B, Loven K, Shalita A. Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double-blind, randomized parallelgroup trial. J Drugs Dermatol. 2006 Mar;5(3):256-61.